Overview
Spherix’s coverage of the systemic lupus erythematosus market focuses on rheumatologists’ understanding, diagnosis, and treatment of the disease. Learnings include brand use, factors in brand selection and criteria for evaluating success.
Services Available
Exploring the patient journey
Lupus Nephritis (US) - n=1,000 patient charts
Systemic Lupus Erythematosus (US) - n=1,000 patient charts
Systemic Lupus Erythematosus (EU) - n=1,250 patient charts
Prepping for the pipeline
Lupus Nephritis (US)
Systemic Lupus Erythematosus (US)
Benchmarking new brand performance
Saphnelo (AstraZeneca) in Systemic Lupus Erythematosus (US)
Benlysta (GSK) and Lupkynis (Aurinia) in Lupus Nephritis (US)
Gauging impact of disruptive events
Multi-Specialty Impact of COVID-19 (US)